|
T0160 |
Anagrelide
|
Anagrelida,Xagrid,Anagrelidum |
PDE
|
|
Anagrelide (Xagrid) is a Platelet-reducing Agent. The mechanism of action of anagrelide is as a Phosphodiesterase 3 Inhibitor. The physiologic effect of anagrelide is by means of Decreased Platelet Production. |
|
T4570 |
Pipobroman
|
Vercyte,A-8103,Amedel |
Others
,
DNA Alkylator/Crosslinker
|
|
Pipobroman (Vercyte) is an anti-cancer drug that probably acts as an alkylating agent. Pipobroman has well documented clinical activity in polycythemia vera (PV) and essential thrombocythemia (ET). Pipobroman allows, wit... |
|
T1995 |
Fedratinib
|
TG-101348,SAR 302503 |
Apoptosis
,
FLT
,
c-RET
,
JAK
|
|
Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3. |
|
T9251 |
Fedratinib hydrochloride hydrate
|
TG-101348 hydrochloride hydrate,SAR 302503 hydrochloride hydrate |
Apoptosis
,
JAK
|
|
Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor. |
|
T10009 |
JAK3-IN-7
|
|
JAK
|
|
JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction after organ transplantation, autoimmune disorders, allergic diseases, ... |
|
T71313 |
BVB-808
|
|
|
|
BVB-808 is a selective Jak2 type 1 inhibitor. Janus kinases are critical components of signaling pathways that regulate hematopoiesis. Mutations of the non-receptor tyrosine kinase JAK2 are found in many BCR-ABL-negative... |
|
T76853 |
Ropeginterferon alfa-2b
|
|
|
|
Ropeginterferon alfa-2b (Ropeginterferon alfa-2b-njft), a monopegylated interferon-alpha (IFN-α), is utilized in the study of myeloproliferative neoplasms [1]. |
|
T64227 |
JAK2 JH2 binder-1
|
|
|
|
JAK2 JH2 binder-1 is a potent and selective JAK2 JH2 binder (Ki: 37.1 nM). JAK2 JH2 binder-1 has the potential to be used in the study of various myeloproliferative neoplasms. |
|
T79581 |
JAK2-IN-9
|
|
JAK
|
|
Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM. It effectively inhibits the phosphorylation of JAK2, STAT3, and STAT5, possesses metabolic stabilities, and induces apoptosis. This com... |
|
T9634 |
Bomedemstat
|
|
|
|
Bomedemstat (IMG-7289) is an orally active and irreversible inhibitor of the epigenetically active lysine-specific demethylase 1 (LSD1) in mouse models of myeloproliferative neoplasms (MPNs). Bomedemstat shows antineopla... |
|
T73567 |
ZT55
|
|
|
|
ZT55, an orally active, highly-selective JAK2 inhibitor with an IC50 of 0.031 μM, inhibits proliferation of JAK2 V617F-expressing HEL cell lines, induces apoptosis and cycle arrest, and effectively inhibits HEL xenograft... |
